Patients with Graft-versus-Host Disease from Stem Cell Transplant: We Need Your Help!
Lymphoma Canada, along with an alliance of 8 other blood cancer organizations, is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) and the Quebec equivalent Institut national d’excellence en santé et services sociaux (INESSS) for an upcoming drug review on Ruxolitinib, also known as Jakavi, for the treatment of patients with Graft-versus-Host Disease (GVHD) who have not responded to corticosteroids or other systemic therapies.
Graft-versus-host disease is an acute or chronic condition that can develop after treatment with an allogeneic stem-cell transplant (stem cells from a donor) or a reduced-intensity allogeneic transplant, which you may have received as a treatment for your lymphoma. GVHD develops when the donor’s immune cells mistakenly attach to the patient’s normal cells causing mild, moderate or severe symptoms that may need treatment. Your doctor would tell you if you have been diagnosed with GVHD.
If you have GVHD and have received Ruxolitinib as a treatment, you can help by completing our survey. This survey provides us with patient input required for the submission. pCODR and INESSS use this information to help make recommendations regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, May 14, 2021, and should only take between 10-15 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
